Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Medical Affairs Reputations: Asthma/COPD (US) 2018

Product Code:
596201096
Publication Date:
September 2018
Format:
PowerPoint
Price:
$6,365

Close rivalries among US asthma/COPD medical affairs teams. Will your team come out on top?

In the US, three asthma/COPD medical affairs teams are duking it out for top spot, with less than 2 points separating them. What could teams do to move further ahead or close the gap even more? And can other teams get into the mix of the top 3? 100 pulmonologists and primary care physicians provide insights on several medical affairs teams, and opinions are mixed. Will targeting improvements in certain areas be enough to put your team ahead of the competition?

Discover all the ways you can improve your medical affairs services in Medical Affairs Reputations: Asthma/COPD (US) [2018]. This report, which compares the current activities of medical affairs teams for the 12 leading treatments for asthma/COPD from GSK, Sunovion, Merck & Co., Teva, AstraZeneca, Boehringer Ingelheim, Novartis and Roche, reveals:

  • How pulmonologists and primary care physicians rate your team overall, and on 12 key medical affairs services.
  • Which medical affairs services are most important.
  • How, and how often pulmonologists and primary care physicians want to meet with your team.
  • What you can do to improve your medical affairs services.

That’s actionable information you can use to turn your team into one that doctors rely on.

Interested in the European market? Click here to see the EU5 Edition.

Request sample pages

Top Takeaways

  • Can other teams get into the top 3? With less than 2 points separating the top 3 teams, there’s more than enough room for another team to take the initiative and come out top; but what do they need to do?
  • Information is the #1 priority. The most important medical affairs services all relate to providing information that doctors can use to make better treatment decisions, with nearly all teams tasked with improving in this area.
  • Huge variations in activity. In the past six months, only 2 of 12 teams interacted with more than 70 percent of doctors surveyed, and the least active teams saw just over 30 percent of them.
  • In person or via digital channels? The report reveals how physicians want to interact with rheumatoid arthritis affairs teams. Use this information to refine your medical affairs strategy.

Insight into Medical Affairs Teams for 12 Asthma/COPD Treatments

Inhaled:

  • Advair (fluticasone/salmeterol; GSK)
  • Breo Ellipta (vilanterol/fluticasone furoate; GSK)
  • Dulera (mometasone/formoterol; Merck & Co.)
  • Seebri (glycopyrronium; Sunovion)
  • Spiriva (tiotropium; Boehringer Ingelheim)
  • Symbicort (budesonide/formoterol; AstraZeneca)
  • Utibron (indacaterol/glycopyrronium; Sunovion)
  • Trelegy Ellipta (fluticasone/umeclidinium/vilanterol; GSK)

Biologics:

  • Cinqair (reslizumab; Teva)
  • Fasenra (benralizumab; AstraZeneca)
  • Nucala (mepolizumab; GSK)
  • Xolair (omalizumab; Novartis/Roche)

An Expert-designed Competitive View of Your Medical Affairs Team

Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 12 medical affairs teams—answering important questions like:

What do doctors need?

  • How, and how often are they using your medical affairs team?
  • What services do they consider most important?
  • How often should you contact them? What channels are best?

Does your medical affairs team deliver?

  • How memorable are your team’s interactions with doctors?
  • How do doctors rank your team for performance and satisfaction in 12 key areas?
  • How does your team compare to the competition—in each area, and overall?

What needs improvement?

  • Are you delivering the services that are most important to doctors?
  • Where do you need to improve?
  • How can your team enhance its services?

Based on Interviews with Practicing Doctors

We surveyed 100 US pulmonologists and primary care physicians, chosen from the largest community of validated physicians in the world.

All respondents:

  • Have been practicing for between 3 and 35 years
  • See at least 5 patients with asthma/COPD in a typical month
  • Devote at least 50% of their time to direct patient care
  • Have interacted with at least one listed product’s medical affairs team in the past 6 months

We conducted the survey between September 5-10, 2018.

Money Back Guarantee!

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

  • FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
  • FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Learn more at www.firstwordgroup.com.




customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved